FDA Approves TNKase for Acute Ischemic Stroke
- The U.S. Food and Drug Administration has approved TNKase for treating acute ischemic stroke in adults.
- TNKase is given as a single five-second intravenous bolus, which is faster than the current standard treatment, Activase .
- Genentech's new 25-mg vial of TNKase will be available in the coming months, following the approval.
- Approval was based on a study showing TNKase's efficacy and safety were comparable to Activase.
Insights by Ground AI
Does this summary seem wrong?
31 Articles
31 Articles
All
Left
4
Center
6
Right
2
FDA Approves TNKase for Acute Ischemic Stroke
THURSDAY, March 6, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved TNKase (tenecteplase), a thrombolytic or clot-dissolving agent, for the treatment of acute ischemic stroke in adults.
·Pennsylvania, United States
Read Full ArticleCoverage Details
Total News Sources31
Leaning Left4Leaning Right2Center6Last UpdatedBias Distribution50% Center
Bias Distribution
- 50% of the sources are Center
50% Center
L 33%
C 50%
R 17%
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage